首页> 外文期刊>World Journal of Gastroenterology >The development of a new bioartificial liver and its application in 12 acute liver failure patients
【24h】

The development of a new bioartificial liver and its application in 12 acute liver failure patients

机译:新型生物人工肝的开发及其在12例急性肝衰竭患者中的​​应用

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not. METHODS: Hepatocytes were procured from swine using Seglen's methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10~(10) hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of non-simultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied. RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25 %. CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.
机译:目的:生物人工肝有望支持急性肝功能衰竭患者的肝功能。使用聚砜纤维,开发了一种新的生物人工肝。这项研究的目的是表明这种生物人工肝能否支持肝功能。方法:使用Seglen方法从猪中获得肝细胞。生物人工肝是由聚砜生物反应器和超过10〜(10)个肝细胞构成的。它在12例患者中应用了14次,分为7例同时HBAL和5例非同时HBAL。每次BAL治疗持续6小时。研究了患者的一般情况和生化指标。结果:经生物人工肝治疗后,血氨,凝血酶原时间和总胆红素显着降低。 2天后,血氨仍显示出改善。在一个月内,同期组死亡1例(1/7),非同期组死亡2例(2/5)。差异很大。死亡率为25%。结论:构建的生物人工肝可以支持急性肝衰竭的肝功能。同时HBAL优于非同时HBAL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号